Scarica l'app Stockscreener
53.07
8.46%
4.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally - CoinCentral
CRISPR Therapeutics: A Biotech Stock Poised for Growth - Intellectia AI
Why CRISPR Therapeutics stock is up today (despite its Q4 earnings miss) - MSN
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings - Intellectia AI
ARK Investment’s Strategic Purchase in CRISPR Therapeutics - StocksToTrade
Why Is CRISPR Therapeutics Stock Surging Friday?CRISPR Therapeutics (NASDAQ:CRSP) - Benzinga
CRSP: TD Cowen Raises Price Target Following Hold Rating | CRSP Stock News - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 8% on Analyst Upgrade - MarketBeat
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - TradingView
CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $82.00 - MarketBeat
Needham Raises CRSP Price Target with a Buy Rating | CRSP Stock News - GuruFocus
CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook - TipRanks
Crispr Therapeutics (CRSP) Reports Lower-Than-Expected Q4 Revenue - GuruFocus
Decoding CRISPR Therapeutics AG (CRSP): A Strategic SWOT Insight - GuruFocus
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates - Bitget
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results - MarketBeat
Liquidity Mapping Around (CRSP) Price Events - Stock Traders Daily
Crispr Therapeutics earnings missed by $0.20, revenue fell short of estimates - Investing.com
CRISPR Therapeutics (CRSP) Q4 Earnings Miss Expectations - GuruFocus
CRISPR Therapeutics AG SEC 10-K Report - TradingView
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q4 Revenue $864,000 - marketscreener.com
CRISPR Therapeutics Earnings Report: Q4 Overview - Benzinga
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Is CRISPR Therapeutics AG showing insider buying2025 Volatility Report & Fast Gaining Stock Reports - mfd.ru
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 69.80% Potential Upside - DirectorsTalk Interviews
Guidance Update: Is CRISPR Therapeutics AG backed by strong institutional buyingGlobal Markets & Daily Chart Pattern Signals - baoquankhu1.vn
Aug PreEarnings: Is CRISPR Therapeutics AG backed by strong institutional buyingCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG $CRSP Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline - Finviz
CRISPR Therapeutics AG (CRSP) Stock Analysis: Navigating The 64% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91 - Nasdaq
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - TradingView
Pathway Capital Management LP Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday - MarketBeat
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative? - simplywall.st
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Layoff Watch: Will CRISPR Therapeutics AG benefit from government policyQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Why (CRSP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Brokerages - MarketBeat
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story - simplywall.st
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
Will CRISPR Therapeutics AG stock gain from lower inflationJuly 2025 Setups & Daily Profit Focused Stock Screening - mfd.ru
CRSP: Citizens Analyst Lowers Price Target to $80 | CRSP Stock N - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at Citizens Jmp - MarketBeat
CRISPR Therapeutics stock price target lowered to $80 by Citizens - Investing.com Nigeria
CRISPR Therapeutics CEO Share Sale Tests Confidence In Gene Editing Story - Sahm
ARK Investment Acquires Significant Stake in Crispr Therapeutics (CRSP) - GuruFocus
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch - Finviz
What Does the Market Think About CRISPR Therapeutics AG? - Benzinga
BofA is Bullish on CRISPR Therapeutics AG (CRSP) - Insider Monkey
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):